Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AVEO PHARMACEUTICALS, INC.AVEO · Entity 120602 | Director | February 01, 2018 | February 05, 2018 |
| Applied Therapeutics, Inc.APLT · Entity 67708 | Director · Executive Chairman | December 19, 2024 | December 21, 2024 |
| Axogen, Inc.AXGN · Entity 4297 | Director | June 24, 2026 | June 26, 2026 |
| ELI LILLY & CoLLY · Entity 2794 | Sr. VP, Oncology Business Unit | November 01, 2009 | November 10, 2009 |
| MELINTA THERAPEUTICS, INC. /NEW/MLNT · Entity 154249 | Director · Chief Executive Officer | June 27, 2019 | July 02, 2019 |
| Ocugen, Inc.HSGX · Entity 5550 | Director | June 15, 2018 | June 19, 2018 |
| Strongbridge Biopharma plcSBBP · Entity 131608 | Director · Chief Executive Officer | October 05, 2021 | October 06, 2021 |
| Verastem, Inc.VSTM · Entity 5242 | Director | May 21, 2026 | May 26, 2026 |
| Xeris Biopharma Holdings, Inc.XERS · Entity 4670 | Director | June 04, 2026 | June 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AVEO PHARMACEUTICALS, INC.
Report date February 01, 2018 · Filed February 05, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.08 · Expires 2028-01-31 | Direct | 100,000 |
Reported balance
After 2018-02-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-02-01 · Grant · Acquired 100,000 · Balance 100,000 F1: This option vests in equal monthly installments from March 1, 2018 through February 1, 2021 subject to the Reporting Person's continued service to the company. |
Filing footnotes · ownership attribution and instrument terms
F1: This option vests in equal monthly installments from March 1, 2018 through February 1, 2021 subject to the Reporting Person's continued service to the company.
Applied Therapeutics, Inc.
Report date December 19, 2024 · Filed December 21, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 500,000 |
Reported balance
After 2024-12-19 transaction · row 1
1 source rowRow 1 · 2024-12-19 · Grant · Acquired 500,000 · Balance 500,000 F1: Consists of compensatory Restricted Stock Units ("RSUs") granted outside of Applied Therapeutics, Inc.'s 2019 Equity Incentive Plan pursuant to the inducement grant exception under Nasdaq Rule 5635(c). Each RSU represents a contingent right to receive one share of the issuer's common stock. The RSUs will vest in equal annual installments on each of the first two anniversaries of the grant date, subject to the Reporting Person continuing to provide services through each such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.02 · Expires 2034-12-19 | Direct | 1,000,000 |
Reported balance
After 2024-12-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-12-19 · Grant · Acquired 1,000,000 · Balance 1,000,000 F2: Consists of compensatory Options granted outside of Applied Therapeutics, Inc.'s 2019 Equity Incentive Plan pursuant to the inducement grant exception under Nasdaq Rule 5635(c). The shares subject to the Option will vest in equal annual installments on each of the first two anniversaries of the grant date, subject to the Reporting Person continuing to provide services through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of compensatory Restricted Stock Units ("RSUs") granted outside of Applied Therapeutics, Inc.'s 2019 Equity Incentive Plan pursuant to the inducement grant exception under Nasdaq Rule 5635(c). Each RSU represents a contingent right to receive one share of the issuer's common stock. The RSUs will vest in equal annual installments on each of the first two anniversaries of the grant date, subject to the Reporting Person continuing to provide services through each such date.
F2: Consists of compensatory Options granted outside of Applied Therapeutics, Inc.'s 2019 Equity Incentive Plan pursuant to the inducement grant exception under Nasdaq Rule 5635(c). The shares subject to the Option will vest in equal annual installments on each of the first two anniversaries of the grant date, subject to the Reporting Person continuing to provide services through each such date.
Axogen, Inc.
Report date June 24, 2026 · Filed June 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 4,392 |
Reported balance
After 2026-06-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-24 · Grant · Acquired 4,392 · Balance 4,392 F1: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F2: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $185,000 valuation as of the grant date and vests on June 24, 2027, the one-year anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.
F2: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $185,000 valuation as of the grant date and vests on June 24, 2027, the one-year anniversary of the grant date.
ELI LILLY & Co
Report date November 01, 2009 · Filed November 10, 2009
This filing explicitly reported no securities owned.
MELINTA THERAPEUTICS, INC. /NEW/
Report date June 27, 2019 · Filed July 02, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Melinta Common StockSEC Table I · non-derivative | Direct | 37,400 |
Reported balance
After 2019-06-27 transaction · row 1
1 source rowRow 1 · 2019-06-27 · Sale · Disposed 13,000 · Balance 37,400 F1: Represents the number of shares necessary to cover tax withholding obligations in connection with the vesting of the Reporting Person's RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares necessary to cover tax withholding obligations in connection with the vesting of the Reporting Person's RSUs.
Ocugen, Inc.
Report date June 15, 2018 · Filed June 19, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.97 · Expires 2028-06-14 | Direct | 25,000 |
Reported balance
After 2018-06-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-06-15 · Grant · Acquired 25,000 · Balance 25,000 F1: This option vests and becomes exercisable with respect to 8.33% of the option shares for each one-month period following June 15, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: This option vests and becomes exercisable with respect to 8.33% of the option shares for each one-month period following June 15, 2018.
Strongbridge Biopharma plc
Report date October 05, 2021 · Filed October 06, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-10-05 transaction · row 1
1 source rowRow 1 · 2021-10-05 · Disposition to issuer · Disposed 610,092 · Balance 0 F1: Ordinary shares of Issuer were converted into shares of common stock of Xeris Biopharma Holdings, Inc. ("HoldCo") pursuant to the Transaction Agreement (the "Agreement"), dated May 24, 2021, among the Issuer, Xeris Pharmaceuticals, Inc., HoldCo and Wells MergerSub, Inc. Under the Agreement, each ordinary share of Issuer was exchanged for 0.784 of a share of HoldCo common stock, and cash in lieu of fractional shares, plus one contingent value right (a "CVR") worth up to an additional $1.00, payable in cash, HoldCo common stock or a combination thereof at HoldCo's sole election. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-10-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-10-05 · Disposition to issuer · Disposed 495,724 · Balance 0 F2: Under the Agreement, each option to purchase ordinary shares of Issuer was automatically converted into an option to acquire a number of shares of HoldCo common stock determined by multiplying the number of ordinary shares of Issuer subject to such option by 0.784 (rounded down to the nearest whole share), at an exercise price per share (rounded up to the nearest whole cent) determined by dividing the per-share exercise price of Issuer option by 0.784, with the same terms and conditions as applied to the applicable option prior to closing of the transaction. HoldCo issued one CVR with respect to each ordinary share of Issuer subject to each option prior to the adjustment described herein, subject to the same vesting and forfeiture conditions applicable to the corresponding option. |
Filing footnotes · ownership attribution and instrument terms
F1: Ordinary shares of Issuer were converted into shares of common stock of Xeris Biopharma Holdings, Inc. ("HoldCo") pursuant to the Transaction Agreement (the "Agreement"), dated May 24, 2021, among the Issuer, Xeris Pharmaceuticals, Inc., HoldCo and Wells MergerSub, Inc. Under the Agreement, each ordinary share of Issuer was exchanged for 0.784 of a share of HoldCo common stock, and cash in lieu of fractional shares, plus one contingent value right (a "CVR") worth up to an additional $1.00, payable in cash, HoldCo common stock or a combination thereof at HoldCo's sole election.
F2: Under the Agreement, each option to purchase ordinary shares of Issuer was automatically converted into an option to acquire a number of shares of HoldCo common stock determined by multiplying the number of ordinary shares of Issuer subject to such option by 0.784 (rounded down to the nearest whole share), at an exercise price per share (rounded up to the nearest whole cent) determined by dividing the per-share exercise price of Issuer option by 0.784, with the same terms and conditions as applied to the applicable option prior to closing of the transaction. HoldCo issued one CVR with respect to each ordinary share of Issuer subject to each option prior to the adjustment described herein, subject to the same vesting and forfeiture conditions applicable to the corresponding option.
Verastem, Inc.
Report date May 21, 2026 · Filed May 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 52,666 |
Reported balance
After 2026-05-21 transaction · row 1
1 source rowRow 1 · 2026-05-21 · Grant · Acquired 36,000 · Balance 52,666 F1: RSUs granted to the Reporting Person under the Issuer's Amended and Restated 2021 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Common Stock. The RSUs vest in twelve substantially equal installments (rounded down to the nearest whole share on each vesting date except with respect to the final vesting date on which the remaining unvested portion shall vest). The first eleven installments shall vest beginning on the last day of each month over a period from June, 2026 to April, 2027 and the last installment shall vest on the earlier of (i) the day before the 2027 Annual Meeting of Stockholders is held or (ii) May 31, 2027, provided that the Reporting Person continues to serve as a director of the Issuer on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: RSUs granted to the Reporting Person under the Issuer's Amended and Restated 2021 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Common Stock. The RSUs vest in twelve substantially equal installments (rounded down to the nearest whole share on each vesting date except with respect to the final vesting date on which the remaining unvested portion shall vest). The first eleven installments shall vest beginning on the last day of each month over a period from June, 2026 to April, 2027 and the last installment shall vest on the earlier of (i) the day before the 2027 Annual Meeting of Stockholders is held or (ii) May 31, 2027, provided that the Reporting Person continues to serve as a director of the Issuer on each such vesting date.
Xeris Biopharma Holdings, Inc.
Report date June 04, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 707,276 |
Ending reported balance
After 2026-06-04 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-06-04 · Sale · Disposed 15,000 · Balance 683,083 F1: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 13, 2025. F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.970 to $6.170, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Row 2 · 2026-06-04 · Grant · Acquired 24,193 · Balance 707,276 F3: These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan (the "Plan"). Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in full upon the earlier to occur of June 4, 2026 or the date of the Company's next annual meeting of stockholders, subject to continued service through such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.15 · Expires 2036-06-04 | Direct | 32,996 |
Reported balance
After 2026-06-04 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-04 · Grant · Acquired 32,996 · Balance 32,996 F4: These stock options were acquired pursuant to a grant under the Plan. These stock options shall vest in full upon the earlier to occur of June 4, 2026 or the date of the Company's next annual meeting of stockholders, subject to continued service through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 13, 2025.
F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.970 to $6.170, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3: These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan (the "Plan"). Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in full upon the earlier to occur of June 4, 2026 or the date of the Company's next annual meeting of stockholders, subject to continued service through such vesting date.
F4: These stock options were acquired pursuant to a grant under the Plan. These stock options shall vest in full upon the earlier to occur of June 4, 2026 or the date of the Company's next annual meeting of stockholders, subject to continued service through such vesting date.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
PORTOLA PHARMACEUTICALS INC
Report date July 02, 2020 · Filed July 02, 2020
Section 16 reporting ended · disclosed 2020-07-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-07-02 transaction · row 1
1 source rowRow 1 · 2020-07-02 · Disposition to issuer · Disposed 13,194 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of May 5, 2020, by and among Portola Pharmaceuticals, Inc. (the "Issuer"), Alexion Pharmaceuticals, Inc. ("Alexion") and Odyssey Merger Sub Inc. ("Merger Sub") (the "Merger Agreement"), on July 2, 2020, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a direct, wholly owned subsidiary of Alexion (the "Merger"). At the effective time of the Merger (the "Effective Time"), these shares were canceled in exchange for $18.00 per share in cash, without interest and subject to any applicable withholding taxes. |
| Restricted Stock UnitsSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-07-02 transaction · row 2
1 source rowRow 2 · 2020-07-02 · Disposition to issuer · Disposed 7,281 · Balance 0 F2: At the Effective Time, each restricted stock unit ("RSU") was accelerated and canceled as of immediately prior to, and contingent upon, the Effective Time, in exchange for the right to receive a cash amount equal to the product of (i) the number of shares deliverable under such RSU multiplied by (ii) $18.00. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.94 · Expires 2030-06-11 | Direct | 0 |
Reported balance
After 2020-07-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-07-02 · Disposition to issuer · Disposed 11,377 · Balance 0 F3: At the Effective Time, each of these unvested and outstanding options was accelerated, canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-07-02 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-07-02 · Disposition to issuer · Disposed 54,991 · Balance 0 F4: In connection with the Merger, these options were accelerated and canceled without payment. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated as of May 5, 2020, by and among Portola Pharmaceuticals, Inc. (the "Issuer"), Alexion Pharmaceuticals, Inc. ("Alexion") and Odyssey Merger Sub Inc. ("Merger Sub") (the "Merger Agreement"), on July 2, 2020, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a direct, wholly owned subsidiary of Alexion (the "Merger"). At the effective time of the Merger (the "Effective Time"), these shares were canceled in exchange for $18.00 per share in cash, without interest and subject to any applicable withholding taxes.
F2: At the Effective Time, each restricted stock unit ("RSU") was accelerated and canceled as of immediately prior to, and contingent upon, the Effective Time, in exchange for the right to receive a cash amount equal to the product of (i) the number of shares deliverable under such RSU multiplied by (ii) $18.00.
F3: At the Effective Time, each of these unvested and outstanding options was accelerated, canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law.
F4: In connection with the Merger, these options were accelerated and canceled without payment.
Sucampo Pharmaceuticals, Inc.
Report date February 13, 2018 · Filed February 13, 2018
Section 16 reporting ended · disclosed 2018-02-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, Class ASEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-02-13 transaction · row 1
1 source rowRow 1 · 2018-02-13 · Disposition to issuer · Disposed 5,130 · Balance 0 F1: This common stock was purchased for $18.00 per share share in cash, subject to any required withholding of taxes and without interest, upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to that certain Agreement and Plan of Merger by and among Mallinckrodt plc, Sun Acquisition Co. and Sucampo Pharmaceuticals, Inc. dated December 23, 2017 (the "Merger Agreement"). The common stock consisted of restricted stock units that were accelerated as a result of the Merger Agreement. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.92 · Expires 2024-12-10 | Direct | 0 |
Reported balance
After 2018-02-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-02-13 · Disposition to issuer · Disposed 30,000 · Balance 0 F2: This option was cancelled and converted into the right to receive in cash the amount per share by which $18.00 exceeds the exercise price of the option, subject to any applicable tax witholdings (such amount, the "Option Spread"), upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to the Merger Agreement. The Option Spread for the unvested portion of the option, if any, will be paid in accordance with the schedule described in the Merger Agreement. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.23 · Expires 2025-05-29 | Direct | 0 |
Reported balance
After 2018-02-13 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-02-13 · Disposition to issuer · Disposed 20,000 · Balance 0 F2: This option was cancelled and converted into the right to receive in cash the amount per share by which $18.00 exceeds the exercise price of the option, subject to any applicable tax witholdings (such amount, the "Option Spread"), upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to the Merger Agreement. The Option Spread for the unvested portion of the option, if any, will be paid in accordance with the schedule described in the Merger Agreement. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.30 · Expires 2025-05-29 | Direct | 0 |
Reported balance
After 2018-02-13 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-02-13 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: This option was cancelled and converted into the right to receive in cash the amount per share by which $18.00 exceeds the exercise price of the option, subject to any applicable tax witholdings (such amount, the "Option Spread"), upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to the Merger Agreement. The Option Spread for the unvested portion of the option, if any, will be paid in accordance with the schedule described in the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: This common stock was purchased for $18.00 per share share in cash, subject to any required withholding of taxes and without interest, upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to that certain Agreement and Plan of Merger by and among Mallinckrodt plc, Sun Acquisition Co. and Sucampo Pharmaceuticals, Inc. dated December 23, 2017 (the "Merger Agreement"). The common stock consisted of restricted stock units that were accelerated as a result of the Merger Agreement.
F2: This option was cancelled and converted into the right to receive in cash the amount per share by which $18.00 exceeds the exercise price of the option, subject to any applicable tax witholdings (such amount, the "Option Spread"), upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to the Merger Agreement. The Option Spread for the unvested portion of the option, if any, will be paid in accordance with the schedule described in the Merger Agreement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 24, 2026 Filed Jun 26, 2026 20:53 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantRestricted Stock Units · Derivative | 4,392 | $0.00 | $0.00 |
DisclosureSEC source: 0001410781-26-000008 · wk-form4_1782507185.xml · derivative · entry 1 JOHNSON JOHN · CIK 0001410781 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,392 Underlying: Common Stock · 4,392 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F2 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $185,000 valuation as of the grant date and vests on June 24, 2027, the one-year anniversary of the grant date. F2 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $185,000 valuation as of the grant date and vests on June 24, 2027, the one-year anniversary of the grant date. Read SEC document |
| June 19, 2026 Filed Jun 23, 2026 20:35 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionRestricted Stock Units · Derivative | 14,150 | $0.00 | $0.00 |
DisclosureSEC source: 0001410781-26-000006 · wk-form4_1782246942.xml · derivative · entry 2 JOHNSON JOHN · CIK 0001410781 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,150 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F3 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on June 19, 2026, the one-year anniversary of the grant date. F3 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on June 19, 2026, the one-year anniversary of the grant date. Read SEC document |
| June 19, 2026 Filed Jun 23, 2026 20:35 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 14,150 | $0.00 | $0.00 |
DisclosureSEC source: 0001410781-26-000006 · wk-form4_1782246942.xml · nonDerivative · entry 1 JOHNSON JOHN · CIK 0001410781 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,150 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This reflects the number of restricted stock units that vested June 19, 2026. Read SEC document |
| June 04, 2026 Filed Jun 5, 2026 22:17 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | GrantStock Option (Right to Buy) · Derivative | 32,996 | $6.15 Strike: $6.15 | $202,925.40 |
DisclosureSEC source: 0001410781-26-000004 · wk-form4_1780697874.xml · derivative · entry 3 JOHNSON JOHN · CIK 0001410781 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,996 Underlying: Common Stock · 32,996 shares Expires 2036-06-04 F4 · derivative.exercise_date: These stock options were acquired pursuant to a grant under the Plan. These stock options shall vest in full upon the earlier to occur of June 4, 2026 or the date of the Company's next annual meeting of stockholders, subject to continued service through such vesting date. Read SEC document |
| June 04, 2026 Filed Jun 5, 2026 22:17 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | GrantCommon Stock | 24,193 | $0.00 | $0.00 |
DisclosureSEC source: 0001410781-26-000004 · wk-form4_1780697874.xml · nonDerivative · entry 2 JOHNSON JOHN · CIK 0001410781 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 707,276 F3 · shares: These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan (the "Plan"). Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in full upon the earlier to occur of June 4, 2026 or the date of the Company's next annual meeting of stockholders, subject to continued service through such vesting date. Read SEC document |
| June 04, 2026 Filed Jun 5, 2026 22:17 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | SaleCommon Stock | 15,000 | $6.09 | $91,422.00 |
DisclosureSEC source: 0001410781-26-000004 · wk-form4_1780697874.xml · nonDerivative · entry 1 JOHNSON JOHN · CIK 0001410781 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 683,083 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 13, 2025. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.970 to $6.170, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 21, 2026 Filed May 26, 2026 22:12 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantCommon Stock | 36,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-066412 · tm2615478-4_4seq1.xml · nonDerivative · entry 1 JOHNSON JOHN · CIK 0001410781 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,666 F1 · shares: RSUs granted to the Reporting Person under the Issuer's Amended and Restated 2021 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Common Stock. The RSUs vest in twelve substantially equal installments (rounded down to the nearest whole share on each vesting date except with respect to the final vesting date on which the remaining unvested portion shall vest). The first eleven installments shall vest beginning on the last day of each month over a period from June, 2026 to April, 2027 and the last installment shall vest on the earlier of (i) the day before the 2027 Annual Meeting of Stockholders is held or (ii) May 31, 2027, provided that the Reporting Person continues to serve as a director of the Issuer on each such vesting date. Read SEC document |
| May 07, 2026 Filed May 8, 2026 20:07 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionEmployee Stock Option (right to purchase) · Derivative | 11,050 | $0.00 Strike: $7.04 | $0.00 |
DisclosureSEC source: 0001410781-26-000002 · wk-form4_1778270876.xml · derivative · entry 3 JOHNSON JOHN · CIK 0001410781 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,050 shares Expires 2034-06-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: All shares of Axogen, Inc. common stock underlying the board of director stock option were fully vested on June 6, 2025. Read SEC document |
| May 07, 2026 Filed May 8, 2026 20:07 UTC | Axogen, Inc. AXGN · Entity 4297 | SaleCommon Stock | 11,050 | $43.26 | $477,967.75 |
DisclosureSEC source: 0001410781-26-000002 · wk-form4_1778270876.xml · nonDerivative · entry 2 JOHNSON JOHN · CIK 0001410781 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $43.25 to $43.35 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| May 07, 2026 Filed May 8, 2026 20:07 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 11,050 | $7.04 | $77,792.00 |
DisclosureSEC source: 0001410781-26-000002 · wk-form4_1778270876.xml · nonDerivative · entry 1 JOHNSON JOHN · CIK 0001410781 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,050 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 19, 2025 Filed Dec 19, 2025 22:17 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | SaleCommon Stock | 135,400 | $7.22 | $977,019.32 |
DisclosureSEC source: 0001410781-25-000006 · wk-form4_1766182662.xml · nonDerivative · entry 1 JOHNSON JOHN · CIK 0001410781 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 698,083 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.200 to $7.275, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 09, 2025 Filed Dec 10, 2025 22:19 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionStock Option (right to purchase) · Derivative | 8,545 | $0.00 Strike: $6.30 | $0.00 |
DisclosureSEC source: 0001410781-25-000004 · wk-form4_1765405138.xml · derivative · entry 8 JOHNSON JOHN · CIK 0001410781 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,545 shares Expires 2033-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Non-qualified stock option portion of the 2023 annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The grant became fully vested on September 1, 2024, the one-year anniversary of the grant date. Read SEC document |
| December 09, 2025 Filed Dec 10, 2025 22:19 UTC | Axogen, Inc. AXGN · Entity 4297 | SaleCommon Stock | 13,141 | $29.98 | $393,993.46 |
DisclosureSEC source: 0001410781-25-000004 · wk-form4_1765405138.xml · nonDerivative · entry 6 JOHNSON JOHN · CIK 0001410781 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F3 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $29.90 to $30.09 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| December 09, 2025 Filed Dec 10, 2025 22:19 UTC | Axogen, Inc. AXGN · Entity 4297 | SaleCommon Stock | 8,545 | $29.98 | $256,196.19 |
DisclosureSEC source: 0001410781-25-000004 · wk-form4_1765405138.xml · nonDerivative · entry 5 JOHNSON JOHN · CIK 0001410781 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,141 F2 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $29.98 to $30.02 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| December 09, 2025 Filed Dec 10, 2025 22:19 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 8,545 | $6.30 | $53,833.50 |
DisclosureSEC source: 0001410781-25-000004 · wk-form4_1765405138.xml · nonDerivative · entry 4 JOHNSON JOHN · CIK 0001410781 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,686 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 22:19 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionStock Option (right to purchase) · Derivative | 11,891 | $0.00 Strike: $6.30 | $0.00 |
DisclosureSEC source: 0001410781-25-000004 · wk-form4_1765405138.xml · derivative · entry 7 JOHNSON JOHN · CIK 0001410781 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,545 Underlying: Common Stock · 11,891 shares Expires 2033-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Non-qualified stock option portion of the 2023 annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The grant became fully vested on September 1, 2024, the one-year anniversary of the grant date. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 22:19 UTC | Axogen, Inc. AXGN · Entity 4297 | SaleCommon Stock | 11,891 | $31.22 | $371,272.69 |
DisclosureSEC source: 0001410781-25-000004 · wk-form4_1765405138.xml · nonDerivative · entry 3 JOHNSON JOHN · CIK 0001410781 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,141 F1 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $31.00 to $31.57 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 22:19 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 11,891 | $6.30 | $74,913.30 |
DisclosureSEC source: 0001410781-25-000004 · wk-form4_1765405138.xml · nonDerivative · entry 2 JOHNSON JOHN · CIK 0001410781 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,032 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 22:19 UTC | Axogen, Inc. AXGN · Entity 4297 | SaleCommon Stock | 11,802 | $31.26 | $368,930.52 |
DisclosureSEC source: 0001410781-25-000004 · wk-form4_1765405138.xml · nonDerivative · entry 1 JOHNSON JOHN · CIK 0001410781 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,141 F1 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $31.00 to $31.57 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| August 13, 2025 Filed Aug 15, 2025 20:57 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | SaleCommon Stock | 107,500 | $7.32 | $786,459.25 |
DisclosureSEC source: 0001867096-25-000141 · wk-form4_1755291454.xml · nonDerivative · entry 1 JOHNSON JOHN · CIK 0001410781 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 833,483 F1 · price: The price reported in is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.250 to $7.420, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 19, 2025 Filed Jun 20, 2025 20:11 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantRestricted Stock Units · Derivative | 14,150 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-25-000102 · wk-form4_1750450260.xml · derivative · entry 1 JOHNSON JOHN · CIK 0001410781 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,150 Underlying: Common Stock · 14,150 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F2 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on June 19, 2026, the one-year anniversary of the grant date. F2 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on June 19, 2026, the one-year anniversary of the grant date. Read SEC document |
| June 09, 2025 Filed Jun 11, 2025 20:23 UTC | Axogen, Inc. AXGN · Entity 4297 | SaleCommon Stock | 4,073 | $10.61 | $43,214.53 |
DisclosureSEC source: 0000805928-25-000081 · wk-form4_1749673393.xml · nonDerivative · entry 1 JOHNSON JOHN · CIK 0001410781 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,943 F1 · shares: The reported price in Column 4 is a weighted average sale price. These shares were sold on June 9, 2025, in multiple transactions at prices ranging from $10.47 to $10.61 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units. Read SEC document |
| June 04, 2025 Filed Jun 4, 2025 23:01 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001867096-25-000108 · wk-form4_1749078084.xml · nonDerivative · entry 1 JOHNSON JOHN · CIK 0001410781 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 940,983 F1 · shares: These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in full upon the earlier to occur of June 4, 2026 or the date of the Company's next annual meeting of stockholders. Read SEC document |
| May 22, 2025 Filed May 27, 2025 21:42 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $7.48 | $0.00 |
DisclosureSEC source: 0001104659-25-053093 · tm2516118-2_4seq1.xml · derivative · entry 2 JOHNSON JOHN · CIK 0001410781 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2035-05-22 F2 · derivative.exercise_date: The stock option vests in twelve equal installments (rounded down to the nearest whole share on each vesting date except with respect to the final vesting date on which the remaining unvested portion shall vest). The first eleven installments shall vest beginning on the last day of each month over a period from June, 2025 to April, 2026 and the last installment shall vest on the earlier of (i) the day before the 2026 Annual Meeting of Stockholders is held or (ii) May 31, 2026, provided that the Reporting Person continues to serve as a director of the Issuer on each such vesting date. Read SEC document |
| May 22, 2025 Filed May 27, 2025 21:42 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantCommon Stock | 8,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-053093 · tm2516118-2_4seq1.xml · nonDerivative · entry 1 JOHNSON JOHN · CIK 0001410781 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,666 F1 · shares: RSUs granted to the Reporting Person under the Issuer's Amended and Restated 2021 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Common Stock. The RSUs vest in twelve equal installments (rounded down to the nearest whole share on each vesting date except with respect to the final vesting date on which the remaining unvested portion shall vest). The first eleven installments shall vest beginning on the last day of each month over a period from June, 2025 to April, 2026 and the last installment shall vest on the earlier of (i) the day before the 2026 Annual Meeting of Stockholders is held or (ii) May 31, 2026, provided that the Reporting Person continues to serve as a director of the Issuer on each such vesting date. Read SEC document |
| December 19, 2024 Filed Dec 21, 2024 01:30 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | GrantStock Option (Right to Buy) · Derivative | 1,000,000 | $0.00 Strike: $1.02 | $0.00 |
DisclosureSEC source: 0000950170-24-139240 · ownership.xml · derivative · entry 2 JOHNSON JOHN · CIK 0001410781 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,000,000 Underlying: Common Stock · 1,000,000 shares Expires 2034-12-19 F2 · shares: Consists of compensatory Options granted outside of Applied Therapeutics, Inc.'s 2019 Equity Incentive Plan pursuant to the inducement grant exception under Nasdaq Rule 5635(c). The shares subject to the Option will vest in equal annual installments on each of the first two anniversaries of the grant date, subject to the Reporting Person continuing to provide services through each such date. F2 · derivative.exercise_date: Consists of compensatory Options granted outside of Applied Therapeutics, Inc.'s 2019 Equity Incentive Plan pursuant to the inducement grant exception under Nasdaq Rule 5635(c). The shares subject to the Option will vest in equal annual installments on each of the first two anniversaries of the grant date, subject to the Reporting Person continuing to provide services through each such date. Read SEC document |
| December 19, 2024 Filed Dec 21, 2024 01:30 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | GrantCommon Stock | 500,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-139240 · ownership.xml · nonDerivative · entry 1 JOHNSON JOHN · CIK 0001410781 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 500,000 F1 · shares: Consists of compensatory Restricted Stock Units ("RSUs") granted outside of Applied Therapeutics, Inc.'s 2019 Equity Incentive Plan pursuant to the inducement grant exception under Nasdaq Rule 5635(c). Each RSU represents a contingent right to receive one share of the issuer's common stock. The RSUs will vest in equal annual installments on each of the first two anniversaries of the grant date, subject to the Reporting Person continuing to provide services through each such date. Read SEC document |
| September 01, 2024 Filed Sep 5, 2024 01:13 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionRestricted Stock Units · Derivative | 11,904 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-24-000121 · wk-form4_1725498802.xml · derivative · entry 2 JOHNSON JOHN · CIK 0001410781 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,904 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F3 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on September 1, 2024, one year anniversary of the grant date. F3 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on September 1, 2024, one year anniversary of the grant date. Read SEC document |
| September 01, 2024 Filed Sep 5, 2024 01:13 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 11,904 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-24-000121 · wk-form4_1725498802.xml · nonDerivative · entry 1 JOHNSON JOHN · CIK 0001410781 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,016 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This reflects the number of restricted stock units that vested on September 1, 2024. Read SEC document |
| June 18, 2024 Filed Jun 21, 2024 00:27 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $3.27 | $0.00 |
DisclosureSEC source: 0001104659-24-073599 · tm2417704-7_4seq1.xml · derivative · entry 2 JOHNSON JOHN · CIK 0001410781 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2034-06-18 F2 · derivative.exercise_date: The stock option vests in twelve equal installments (rounded down to the nearest whole share on each vesting date except with respect to the final vesting date on which the remaining unvested portion shall vest). The first eleven installments shall vest beginning on the last day of each month over a period from June, 2024 to April, 2025 and the last installment shall vest on the earlier of (i) the day before the 2025 Annual Meeting of Stockholders is held or (ii) May 31, 2025, provided that the Reporting Person continues to serve as a director of the Issuer on each such vesting date. Read SEC document |
| June 18, 2024 Filed Jun 21, 2024 00:27 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantCommon Stock | 8,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-073599 · tm2417704-7_4seq1.xml · nonDerivative · entry 1 JOHNSON JOHN · CIK 0001410781 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,333 F1 · shares: Restricted stock units ("RSUs") granted to the Reporting Person under the Issuer's Amended and Restated 2021 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Common Stock. The RSUs vest in twelve equal installments (rounded down to the nearest whole share on each vesting date except with respect to the final vesting date on which the remaining unvested portion shall vest). The first eleven installments shall vest beginning on the last day of each month over a period from June, 2024 to April, 2025 and the last installment shall vest on the earlier of (i) the day before the 2025 Annual Meeting of Stockholders is held or (ii) May 31, 2025, provided that the Reporting Person continues to serve as a director of the Issuer on each such vesting date. Read SEC document |
| June 06, 2024 Filed Jun 10, 2024 22:20 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantEmployee Stock Option (right to purchase) · Derivative | 18,248 | $0.00 Strike: $7.04 | $0.00 |
DisclosureSEC source: 0000805928-24-000099 · wk-form4_1718058050.xml · derivative · entry 2 JOHNSON JOHN · CIK 0001410781 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,248 Underlying: Common Stock · 18,248 shares Expires 2034-06-06 F2 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on June 6, 2025, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units. Read SEC document |
| June 06, 2024 Filed Jun 10, 2024 22:20 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantCommon Stock | 10,653 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000805928-24-000099 · wk-form4_1718058050.xml · nonDerivative · entry 1 JOHNSON JOHN · CIK 0001410781 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,112 F1 · price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. Read SEC document |
| June 05, 2024 Filed Jun 5, 2024 20:18 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001867096-24-000106 · wk-form4_1717618723.xml · nonDerivative · entry 1 JOHNSON JOHN · CIK 0001410781 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 890,983 F1 · shares: These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in full upon the earlier to occur of June 5, 2025 or the date of the Company's next annual meeting of stockholders. Read SEC document |
| March 18, 2024 Filed Mar 18, 2024 21:32 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | Exercise / conversionStock Option (Right to Buy) · Derivative | 215,600 | $0.00 Strike: $1.99 | $0.00 |
DisclosureSEC source: 0001867096-24-000036 · wk-form4_1710797522.xml · derivative · entry 2 JOHNSON JOHN · CIK 0001410781 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 215,600 shares Expires 2029-11-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The options to purchase shares of Xeris Biopharma Holdings Inc. common stock fully vested on October 5, 2021. Read SEC document |
| March 18, 2024 Filed Mar 18, 2024 21:32 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | Exercise / conversionCommon Stock | 215,600 | $1.99 | $429,044.00 |
DisclosureSEC source: 0001867096-24-000036 · wk-form4_1710797522.xml · nonDerivative · entry 1 JOHNSON JOHN · CIK 0001410781 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 751,412 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 15, 2024 Filed Apr 1, 2024 21:43 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | OtherCommon Stock | 89,571 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001867096-24-000039 · wk-form4_1712007768.xml · nonDerivative · entry 1 JOHNSON JOHN · CIK 0001410781 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 840,983 F1 · kind: Keveyis Sales 2023 Milestone achieved resulting in the settlement of the related Contingent Value Right ("CVR") in shares of Xeris Biopharma Holdings, Inc. (the "Company")'s Common Stock. F2 · shares: The reporting person's right to receive additional shares pursuant to this earn-out right became fixed and irrevocable on October 5, 2021, the effective time of the Merger (as defined below), pursuant to the transaction agreement dated as of May 24, 2021 by and among Xeris Pharmaceuticals, Inc. ("Xeris"), Strongbridge Biopharma plc ("Strongbridge"), the Issuer ("HoldCo") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo ("MergerSub"), where HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge, and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the "Merger"). F3 · price: The number of shares of Common Stock for the CVR is equal to the product (A) $0.25 divided by the volume weighted average price for the Company's Common Stock as reported by Nasdaq for the ten (10) Trading Days immediately prior to October 5, 2021 and (B) the number of CVRs held by the holder as reflected on the CVR Register. Read SEC document |
| March 11, 2024 Filed Mar 13, 2024 22:14 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantStock Option (right to buy) · Derivative | 8,549 | Not disclosed Strike: $11.44 | Not disclosed |
DisclosureSEC source: 0001104659-24-034041 · tm248737-5_4seq1.xml · derivative · entry 5 JOHNSON JOHN · CIK 0001410781 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,549 Underlying: Common Stock · 8,549 shares Expires 2034-03-11 F1 · price: On March 11, 2024, the Issuer cancelled, pursuant to the Issuer's option exchange program, certain eligible unexercised options with an exercise price greater than $15.00 granted to the Reporting Person. In exchange,the Reporting Person received a grant of 8,549 stock options that will vest in two equal installments over a two-year period from March 11, 2024 (with the number of shares vesting on each vesting date will be rounded down to the nearest whole share, except with respect to the vesting dates on which all remaining unvested shares shall vest), provided the Reporting Person continues to serve as a director of or other service provider to the Issuer on each such vesting date. F1 · derivative.exercise_date: On March 11, 2024, the Issuer cancelled, pursuant to the Issuer's option exchange program, certain eligible unexercised options with an exercise price greater than $15.00 granted to the Reporting Person. In exchange,the Reporting Person received a grant of 8,549 stock options that will vest in two equal installments over a two-year period from March 11, 2024 (with the number of shares vesting on each vesting date will be rounded down to the nearest whole share, except with respect to the vesting dates on which all remaining unvested shares shall vest), provided the Reporting Person continues to serve as a director of or other service provider to the Issuer on each such vesting date. Read SEC document |
| March 11, 2024 Filed Mar 13, 2024 22:14 UTC | Verastem, Inc. VSTM · Entity 5242 | Disposition to issuerStock Option (right to buy) · Derivative | 2,083 | Not disclosed Strike: $49.92 | Not disclosed |
DisclosureSEC source: 0001104659-24-034041 · tm248737-5_4seq1.xml · derivative · entry 4 JOHNSON JOHN · CIK 0001410781 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,083 shares Expires 2031-06-28 F1 · price: On March 11, 2024, the Issuer cancelled, pursuant to the Issuer's option exchange program, certain eligible unexercised options with an exercise price greater than $15.00 granted to the Reporting Person. In exchange,the Reporting Person received a grant of 8,549 stock options that will vest in two equal installments over a two-year period from March 11, 2024 (with the number of shares vesting on each vesting date will be rounded down to the nearest whole share, except with respect to the vesting dates on which all remaining unvested shares shall vest), provided the Reporting Person continues to serve as a director of or other service provider to the Issuer on each such vesting date. F5 · derivative.exercise_date: The canceled stock option was granted on June 28, 2021 and provided for vesting in twelve equal month installments beginning on the on the last day of each month over a period from June 2021 to May 2022. Read SEC document |
| March 11, 2024 Filed Mar 13, 2024 22:14 UTC | Verastem, Inc. VSTM · Entity 5242 | Disposition to issuerStock Option (right to buy) · Derivative | 2,300 | Not disclosed Strike: $21.24 | Not disclosed |
DisclosureSEC source: 0001104659-24-034041 · tm248737-5_4seq1.xml · derivative · entry 3 JOHNSON JOHN · CIK 0001410781 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,300 shares Expires 2030-06-16 F1 · price: On March 11, 2024, the Issuer cancelled, pursuant to the Issuer's option exchange program, certain eligible unexercised options with an exercise price greater than $15.00 granted to the Reporting Person. In exchange,the Reporting Person received a grant of 8,549 stock options that will vest in two equal installments over a two-year period from March 11, 2024 (with the number of shares vesting on each vesting date will be rounded down to the nearest whole share, except with respect to the vesting dates on which all remaining unvested shares shall vest), provided the Reporting Person continues to serve as a director of or other service provider to the Issuer on each such vesting date. F4 · derivative.exercise_date: The canceled stock option was granted on June 16, 2020 and provided for vesting in twelve equal monthly installments beginning on June 30, 2020 and ending on May 31, 2021. Read SEC document |
| March 11, 2024 Filed Mar 13, 2024 22:14 UTC | Verastem, Inc. VSTM · Entity 5242 | Disposition to issuerStock Option (right to buy) · Derivative | 2,083 | Not disclosed Strike: $21.72 | Not disclosed |
DisclosureSEC source: 0001104659-24-034041 · tm248737-5_4seq1.xml · derivative · entry 2 JOHNSON JOHN · CIK 0001410781 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,083 shares Expires 2030-04-29 F1 · price: On March 11, 2024, the Issuer cancelled, pursuant to the Issuer's option exchange program, certain eligible unexercised options with an exercise price greater than $15.00 granted to the Reporting Person. In exchange,the Reporting Person received a grant of 8,549 stock options that will vest in two equal installments over a two-year period from March 11, 2024 (with the number of shares vesting on each vesting date will be rounded down to the nearest whole share, except with respect to the vesting dates on which all remaining unvested shares shall vest), provided the Reporting Person continues to serve as a director of or other service provider to the Issuer on each such vesting date. F3 · derivative.exercise_date: The canceled stock option was granted on April 29, 2020 and provided for vesting in twelve equal monthly beginning on May 29, 2020 and ending on April 29, 2021. Read SEC document |
| March 11, 2024 Filed Mar 13, 2024 22:14 UTC | Verastem, Inc. VSTM · Entity 5242 | Disposition to issuerStock Option (right to buy) · Derivative | 2,083 | Not disclosed Strike: $15.60 | Not disclosed |
DisclosureSEC source: 0001104659-24-034041 · tm248737-5_4seq1.xml · derivative · entry 1 JOHNSON JOHN · CIK 0001410781 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,083 shares Expires 2030-01-03 F1 · price: On March 11, 2024, the Issuer cancelled, pursuant to the Issuer's option exchange program, certain eligible unexercised options with an exercise price greater than $15.00 granted to the Reporting Person. In exchange,the Reporting Person received a grant of 8,549 stock options that will vest in two equal installments over a two-year period from March 11, 2024 (with the number of shares vesting on each vesting date will be rounded down to the nearest whole share, except with respect to the vesting dates on which all remaining unvested shares shall vest), provided the Reporting Person continues to serve as a director of or other service provider to the Issuer on each such vesting date. F2 · derivative.exercise_date: The canceled stock option was granted on January 3, 2020 and provided for cliff vesting on June 3, 2021. Read SEC document |
| September 01, 2023 Filed Sep 7, 2023 10:29 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantRestricted Stock Units · Derivative | 11,904 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-23-000114 · wf-form4_169408255914339.xml · derivative · entry 2 JOHNSON JOHN · CIK 0001410781 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,904 Underlying: Common Stock · 11,904 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on September 1, 2024, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units of which shares will be delivered to the reporting person upon vesting. F1 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on September 1, 2024, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units of which shares will be delivered to the reporting person upon vesting. Read SEC document |
| September 01, 2023 Filed Sep 7, 2023 10:29 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantStock Option (right to purchase) · Derivative | 20,436 | $0.00 Strike: $6.30 | $0.00 |
DisclosureSEC source: 0000805928-23-000114 · wf-form4_169408255914339.xml · derivative · entry 1 JOHNSON JOHN · CIK 0001410781 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,436 Underlying: Common Stock · 20,436 shares Expires 2033-09-01 F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on September 1, 2024, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units of which shares will be delivered to the reporting person upon vesting. Read SEC document |
| June 07, 2023 Filed Jun 7, 2023 20:59 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | GrantCommon Stock | 42,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001867096-23-000099 · wk-form4_1686171564.xml · nonDerivative · entry 1 JOHNSON JOHN · CIK 0001410781 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 535,812 F1 · shares: These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in full upon the earlier to occur of June 7, 2024 or the date of the Company's next annual meeting of stockholders. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 22:53 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionRestricted Stock Units · Derivative | 6,459 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-23-000066 · wf-form4_168600562557232.xml · derivative · entry 2 JOHNSON JOHN · CIK 0001410781 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,459 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F3 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2023, one year from the anniversary of the grant date. F3 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2023, one year from the anniversary of the grant date. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 22:53 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 6,459 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-23-000066 · wf-form4_168600562557232.xml · nonDerivative · entry 1 JOHNSON JOHN · CIK 0001410781 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,459 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This reflects the number of restricted stock units that vested on June 1, 2023. Read SEC document |
| May 15, 2023 Filed May 16, 2023 20:33 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantStock Option (right to buy) · Derivative | 62,500 | $0.00 Strike: $0.42 | $0.00 |
DisclosureSEC source: 0001104659-23-061421 · tm2315836-5_4seq1.xml · derivative · entry 1 JOHNSON JOHN · CIK 0001410781 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,500 Underlying: Common Stock · 62,500 shares Expires 2033-05-15 F1 · derivative.exercise_date: The stock option vests in twelve equal installments (rounded down to the nearest whole share on each vesting date except with respect to the final vesting date on which the remaining unvested portion shall vest). The first eleven installments shall vest beginning on the last day of each month over a period from June, 2023 to April, 2024 and the last installment shall vest on the earlier of (i) the day before the 2024 Annual Meeting of Stockholders is held or (ii) May 31, 2024, provided that the Reporting Person continues to serve as a director of the Company on each such vesting date. Read SEC document |
| June 22, 2022 Filed Jun 24, 2022 20:11 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantStock Option (right to buy) · Derivative | 62,500 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001104659-22-074309 · tm2219034-6_4seq1.xml · derivative · entry 1 JOHNSON JOHN · CIK 0001410781 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,500 Underlying: Common Stock · 62,500 shares Expires 2032-06-22 F1 · derivative.exercise_date: The stock option vests in twelve equal month installments (rounded down to the nearest whole share on each vesting date except with respect to the final vesting date on which the remaining unvested portion shall vest) beginning on the on the last day of each month over a period from June, 2022 to May, 2023, provided that the Reporting Person continues to serve as a director of the Company on each such vesting date. Read SEC document |
| June 08, 2022 Filed Jun 9, 2022 21:13 UTC | Xeris Biopharma Holdings, Inc. XERS · Entity 4670 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $2.10 | $0.00 |
DisclosureSEC source: 0001867096-22-000090 · wf-form4_165480920373949.xml · derivative · entry 2 JOHNSON JOHN · CIK 0001410781 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-06-08 F2 · derivative.exercise_date: Such options will vest in full upon the earlier to occur of June 8, 2023 or the date of the Company's next annual meeting of stockholders. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.